Synonyms: BI-01383298
Compound class:
Synthetic organic
Comment: BI01383298 is a highly potent, selective and irreversible human sodium-coupled citrate transporter SLC13A5 inhibitor that was developed by Boehringer Ingelheim [2]. It is structurally distinct from SLC13A5's substrate, citrate. BI01383298 is available free-of-charge through Boehringer's opnMe programme or from the Structural Genomics Consortium. This inhibitor is suitable for in vitro experiments.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Boehringer Ingelheim.
BI01383298. Accessed on 16/09/2020. Modified on 16/09/2020. opnMe.com, https://opnme.com/molecules/slc13a5-bi01383298? |
2. Kley J, Kauschke S, Pautsch A, Wiedenmayer D. (2018)
Sulfonamides as inhibitors of the uptake of extracellular citrate. Patent number: WO2018104220A1. Assignee: Boehringer Ingelheim. Priority date: 09/12/2016. Publication date: 14/06/2018. |